| scholarly article | Q13442814 |
| P50 | author | Hans Erik Johnsen | Q43196325 |
| Rasmus Sejersten Ripa | Q63733052 | ||
| P2093 | author name string | Jens Kastrup | |
| Birger Hesse | |||
| Yongzhong Wang | |||
| Erik Jørgensen | |||
| P433 | issue | 15 | |
| P921 | main subject | endothelium | Q111140 |
| patient | Q181600 | ||
| angiogenesis | Q539568 | ||
| P304 | page(s) | 1785-1792 | |
| P577 | publication date | 2006-07-06 | |
| P1433 | published in | European Heart Journal | Q2286839 |
| P1476 | title | Intramyocardial injection of vascular endothelial growth factor-A165 plasmid followed by granulocyte-colony stimulating factor to induce angiogenesis in patients with severe chronic ischaemic heart disease | |
| P478 | volume | 27 |
| Q36655337 | Actions and therapeutic potential of G-CSF and GM-CSF in cardiovascular disease |
| Q26822936 | Adipose-derived mesenchymal stromal cells for chronic myocardial ischemia (MyStromalCell Trial): study design |
| Q30480151 | Angiomyogenesis for myocardial repair |
| Q90562166 | Approaches to therapeutic angiogenesis for ischemic heart disease |
| Q37176436 | Biological approaches to ischemic tissue repair: gene- and cell-based strategies |
| Q38733395 | Cardiovascular Gene Therapy: Past, Present, and Future |
| Q37206495 | Cell therapy for ischaemic heart disease: focus on the role of resident cardiac stem cells |
| Q37801614 | Concise review: Insights from normal bone remodeling and stem cell-based therapies for bone repair |
| Q36985904 | Controlled release systems of angiogenic growth factors for cardiovascular diseases |
| Q96685926 | Coronary vessel formation in development and disease: mechanisms and insights for therapy |
| Q36823697 | Current status of cardiovascular gene therapy |
| Q48459462 | Direct intramyocardial mesenchymal stromal cell injections in patients with severe refractory angina: one-year follow-up |
| Q92814856 | Effects of granulocyte colony‑stimulating factor on rabbit carotid and porcine heart models of chronic obliterative arterial disease |
| Q37729183 | Emerging medical treatment for angina pectoris. |
| Q37572568 | Evaluation of mobilized peripheral blood CD34(+) cells from patients with severe coronary artery disease as a source of endothelial progenitor cells |
| Q30157205 | Experimental study of the effects of marrow mesenchymal stem cells transfected with hypoxia-inducible factor-1alpha gene |
| Q37790168 | G-CSF for stem cell therapy in acute myocardial infarction: friend or foe? |
| Q37149710 | G-CSF-initiated myeloid cell mobilization and angiogenesis mediate tumor refractoriness to anti-VEGF therapy in mouse models |
| Q26769595 | Gene Therapy in Cardiac Surgery: Clinical Trials, Challenges, and Perspectives |
| Q37939775 | Gene delivery methods in cardiac gene therapy |
| Q36617570 | Gene targeting in ischemic heart disease and failure: translational and clinical studies |
| Q37776515 | Gene therapy and angiogenesis in patients with coronary artery disease |
| Q38132253 | Gene therapy for heart disease: molecular targets, vectors and modes of delivery to myocardium |
| Q24632135 | Gene therapy for ischemic heart disease |
| Q91788765 | Growth Factor Gene-Modified Mesenchymal Stem Cells in Tissue Regeneration |
| Q37871920 | Hematopoietic cytokines for cardiac repair: mobilization of bone marrow cells and beyond |
| Q37406656 | Human studies of angiogenic gene therapy |
| Q27303518 | Improved Angiogenesis in Response to Localized Delivery of Macrophage-Recruiting Molecules |
| Q38081027 | Mechanistic, technical, and clinical perspectives in therapeutic stimulation of coronary collateral development by angiogenic growth factors |
| Q37608606 | Mesenchymal stromal cell and mononuclear cell therapy in heart disease |
| Q57681732 | Mesenchymal stromal cell derived endothelial progenitor treatment in patients with refractory angina |
| Q37626836 | Mesenchymal stromal cells for cardiovascular repair: current status and future challenges |
| Q45871851 | Mobilization of haematopoietic and non-haematopoietic cells by granulocyte-colony stimulating factor and vascular endothelial growth factor gene therapy in patients with stable severe coronary artery disease |
| Q37176440 | Myocardial repair: from salvage to tissue reconstruction |
| Q37671758 | Non-viral gene therapy for myocardial engineering |
| Q38113171 | Percutaneous approaches for efficient cardiac gene delivery. |
| Q39063811 | RETRACTED: Recent advances in cardiac regeneration: Stem cell, biomaterial and growth factors |
| Q42762366 | Sonic hedgehog-induced functional recovery after myocardial infarction is enhanced by AMD3100-mediated progenitor-cell mobilization |
| Q33348580 | Stem cell therapy: pieces of the puzzle |
| Q38063950 | Stem cells therapy for cardiovascular repair in ischemic heart disease: How to predict and secure optimal outcome? |
| Q37607007 | The use of soluble signals to harness the power of the bone microenvironment for implant therapeutics. |
| Q37734560 | Therapeutic angiogenesis for the management of refractory angina: current concepts |
| Q27023731 | Therapeutic angiogenesis: controlled delivery of angiogenic factors |
| Q37429806 | Toll-like receptor 3 plays a role in myocardial infarction and ischemia/reperfusion injury |
| Q37570669 | Transplantation of endothelial progenitor cells as therapeutics for cardiovascular diseases |
| Q91792396 | Ultrasound-targeted microbubble destruction in gene therapy: A new tool to cure human diseases |
| Q35069886 | Update on gene therapy for myocardial ischaemia and left ventricular systolic dysfunction or heart failure |
| Q37357266 | Update on therapeutic vascularization strategies. |
| Q28260984 | VEGF gene therapy: therapeutic angiogenesis in the clinic and beyond |
| Q33721685 | Vascular endothelial growth factor signaling in hypoxia and inflammation |
| Q42122625 | p53's choice of myocardial death or survival: Oxygen protects infarct myocardium by recruiting p53 on NOS3 promoter through regulation of p53-Lys(118) acetylation. |
Search more.